For type 2 diabetes mellitus. ANDA 79118, held by Aurobindo Pharma Ltd. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 79118 (Metformin Hydrochloride), held by Aurobindo Pharma Ltd, was first approved by FDA on Jul 20, 2012, with 4 approved supplements and 0 published complete response letters.
Metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 20, 2012 | Original application | Approved | None posted |
| Metformin Hydrochloride500MG · tablet, extended release;oral | Metformin Hydrochloride | Rx |
| Metformin Hydrochloride750MG · tablet, extended release;oral | Metformin Hydrochloride | Rx |
| Aug 11, 2026 | Supplement 18Labeling · Standard review | Approved | None posted |
| Apr 15, 2024 | Supplement 16Manufacturing | Approved | None posted |
| Jan 2, 2019 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jan 2, 2019 | Supplement 9Labeling · Standard review | Approved | None posted |
| Jul 20, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters